Q32 Bio Inc. reported a net loss of $7.4 million, or $0.60 per share, for the third quarter of 2025, compared to a net loss of $17.6 million, or $1.46 per share, for the same period in 2024. Research and development expenses decreased to $3.6 million from $14.3 million, primarily due to lower development costs for bempikibart, reduced expenses from the discontinued ADX-097 program, and lower personnel-related costs. General and administrative expenses were $4.0 million, down from $4.5 million, mainly due to decreased personnel and professional service costs. As of September 30, 2025, cash and cash equivalents totaled $49.0 million, expected to fund operations into 2027. The company completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, with a topline data readout expected in mid-2026, and continues dosing in the Part A open-label extension.